MIME fosters and co-ordinates translational medtech research across Monash University faculties, partner hospitals and collaborating medical research institutions. The clinician-led research programs focus on major clinical and health system needs, and integrate expertise from across engineering, information technology, science, biomedical and clinical research to develop new devices, diagnostics, therapeutics, delivery systems and clinical tools.
The MoU, signed by the director of MIME, Professor Jeffrey Rosenfeld AM, OBE, and Leidos Australia technical director Dan Brewer, will focus on the development of innovative technologies and solutions to address human health problems.
"It will foster the development of new technology and IT solutions for human health problems," said Professor Rosenfeld.
"University-industry collaboration is an important goal to create new opportunities for Australian innovation to reach the marketplace."
Brewer added, “Health is a key area for Leidos globally and as we continue to grow domestically, we will be looking to further develop our range of capabilities in this area."
The MoU will also see Leidos Australia and the MIME collaborate on future R&D with the initial contribution including the funding of a PhD research student.
Leidos is one of the primes tendering for Defence's Deployable Health Capability (JP2060 Phase 3), which aims to introduce an entire system (mission system), inclusive of all medical and dental equipment (a turn key solution) and designed to operate as an integrated capability.
The company also signed another MoU with the University of New South Wales to collaborate on research into the development of force protection and biological security for the Australian Defence Force.